Share-Based Compensation (Stock Appreciation Rights Activity) (Details)	3 Months Ended
	May 01, 2021 USD ($) $ / shares shares
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value | $	$ 427,000
Stock Appreciation Rights Activity, Number of Underlying Shares
Number of Underlying Shares, Beginning Balance at February 1, 2020 | shares	384,757
Number of Underlying Shares, Granted | shares	0
Number of Underlying Shares, Exercised | shares	(54,377)
Number of Underlying Shares, Forfeited | shares	(34,150)
Number of Underlying Shares, Ending Balance at August 1, 2020 | shares	296,230
Number of Underlying shares, Stock appreciation rights exercisable | shares	296,230
Number of Underlying Shares, Stock appreciation rights expected to become exercisable | shares	0
Stock Appreciation Rights, Weighted-Average Exercise Price
Weighted-Average Grant Date Fair Value, Beginning Balance at February 1, 2020 | $ / shares	$ 33.04
Weighted-Average Exercise Price, Granted | $ / shares	0
Weighted-Average Exercise Price, Exercised | $ / shares	22.13
Weighted-Average Exercise Price, Forfeited or expired | $ / shares	54.87
Weighted-Average Grant Date Fair Value, Ending Balance at August 1, 2020 | $ / shares	32.53
Weighted-Average Exercise Price, Stock appreciation rights exercisable | $ / shares	32.53
Weighted-Average Exercise Price, Stock appreciation rights expected to become exercisable | $ / shares	$ 0
Aggregate Intrinsic Value, Outstanding | $	$ 2,325,845
Aggregate Intrinsic Value, Stock appreciation rights exercisable | $	2,325,845
Aggregate Intrinsic Value, Stock appreciation rights expected to become exercisable | $	$ 0
Weighted-Average Remaining Contractual Life, Outstanding	3 years 1 month 6 days
Weighted-Average Remaining Contractual Life, Stock appreciation rights exercisable	3 years 1 month 6 days
Weighted Average Remaining Contractual Life, Stock appreciation rights expected to become exercisable	0 years